Qiagen Forms Molecular Dx Joint Venture in Singapore | GenomeWeb
NEW YORK (GenomeWeb News) – Qiagen is starting a joint venture in Singapore with Bio*One Capital, a biomedical investment management company based in that country, that will develop molecular diagnostic assays for genetic and infectious diseases, the firms said today.
The venture, called Dx Assays, should be operational by early 2008 and will be staffed with over 30 researchers, the companies said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.